Calidi Biotherapeutics Inc. (CLDI)
CLDI trades on NYSE in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$0.8999
-5.26% on the day
Market cap
$3.3M
Nano cap
Revenue
No annual revenue filed since the period ending 2022-12-31
Net income
No annual revenue filed since the period ending 2022-12-31
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | CLDI on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | Not reported by the screener |
| IPO year | 2021 |
| SEC CIK | 0001855485 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials
No annual revenue filed since the period ending 2022-12-31.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-09-17 |
| Latest annual report | 10-K | 2026-03-27 |
| Latest quarterly / interim | 10-Q | 2026-08-13 |
| Latest current report | 8-K | 2026-09-25 |
| Latest proxy | DEFA14A | 2026-06-05 |
Source: SEC EDGAR submissions feed, 406 recent filings. All filings on EDGAR.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| VIVS | VivoSim Labs Inc. | $0.1742 | +0.12% | $2.9M |
| PMCB | PharmaCyte Biotech Inc. | $0.3559 | -2.52% | $3.8M |
| SLXN | Silexion Therapeutics Corp | $0.1760 | -1.24% | $2.5M |
| LIMN | Liminatus Pharma Inc. | $3.41 | -1.16% | $4.6M |
| HLSQ | Tessera Defense and Homeland Security Inc. | $0.2600 | -7.08% | $2.3M |
| BTTC | Black Titan Corporation | $0.4380 | -10.70% | $6.0M |
| CELZ | Creative Medical Technology Holdings Inc. | $0.8199 | -2.51% | $6.2M |
| SCNI | Scinai Immunotherapeutics Ltd. | $1.23 | +6.03% | $1.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier